4.7 Review

Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 70, 期 1, 页码 15-24

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2010.130625

关键词

-

资金

  1. Abbott

向作者/读者索取更多资源

Objective To develop evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis (UPIA). Methods 697 rheumatologists from 17 countries participated in the 3E (Evidence, Expertise, Exchange) Initiative of 2008-9 consisting of three separate rounds of discussions and modified Delphi votes. In the first round 10 clinical questions were selected. A bibliographic team systematically searched Medline, Embase, the Cochrane Library and ACR/EULAR 2007-2008 meeting abstracts. Relevant articles were reviewed for quality assessment, data extraction and synthesis. In the second round each country elaborated a set of national recommendations. Finally, multinational recommendations were formulated and agreement among the participants and the potential impact on their clinical practice was assessed. Results A total of 39 756 references were identified, of which 250 were systematically reviewed. Ten multinational key recommendations about the investigation and follow-up of UPIA were formulated. One recommendation addressed differential diagnosis and investigations prior to establishing the operational diagnosis of UPIA, seven recommendations related to the diagnostic and prognostic value of clinical and laboratory assessments in established UPIA (history and physical examination, acute phase reactants, autoantibodies, radiographs, MRI and ultrasound, genetic markers and synovial biopsy), one recommendation highlighted predictors of persistence (chronicity) and the final recommendation addressed monitoring of clinical disease activity in UPIA. Conclusions Ten recommendations on how to investigate and follow-up UPIA in the clinical setting were developed. They are evidence-based and supported by a large panel of rheumatologists, thus enhancing their validity and practical use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al

Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

Robert B. M. Landewe, Denis Poddubnyy, Proton Rahman, Filip E. Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R. Lisse, So Young Park, Lianne Gensler

Summary: In patients with axial spondyloarthritis who flared after withdrawal of IXE therapy, retreatment with open-label IXE can recapture a certain proportion of patients achieving low disease activity (LDA) or inactive disease (ID).

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Health Care Sciences & Services

Health-related quality of life among spondyloarthritis and chronic low back pain patients: results from a nationwide population-based survey

Helena Santos, Ana Rita Henriques, Jaime Branco, Pedro M. Machado, Helena Canhao, Fernando M. Pimentel-Santos, Ana Maria Rodrigues

Summary: The study found that both spondyloarthritis and chronic low back pain have similar impacts on health-related quality of life (HRQoL), including mental, physical, and social domains. Patients with spondyloarthritis and chronic low back pain reported significantly lower HRQoL compared to those without rheumatic diseases. Modifiable factors such as multimorbidity, active disease, obesity, and regular physical exercise were associated with HRQoL in these conditions.

QUALITY OF LIFE RESEARCH (2023)

Review Rheumatology

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro

Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.

RHEUMATOLOGY (2023)

Article Rheumatology

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen

Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.

RHEUMATOLOGY (2023)

Article Orthopedics

Prevalence of and factors associated with unmanageable pain levels in people with knee or hip osteoarthritis: a cross-sectional population-based study

Daniela Costa, Eduardo B. Cruz, David G. Lopes, Catarina Nunes da Silva, Ana Rita Henriques, Diogo Luis, Jaime Branco, Helena Canhao, Ana M. Rodrigues

Summary: Pain due to knee and/or hip osteoarthritis is a common reason for seeking healthcare. This study aimed to estimate the prevalence of unmanageable pain levels among people with osteoarthritis, identify factors associated with unmanageable pain, and compare therapeutic strategies used by individuals with unmanageable pain versus manageable pain.

BMC MUSCULOSKELETAL DISORDERS (2023)

Article Medicine, General & Internal

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo- controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates, Robert Landewe, Joseph F. Merola, Christopher Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Philip J. Mease

Summary: This study evaluated the efficacy and safety of Bimekizumab in patients with active psoriatic arthritis who were naive to biologic DMARDs. The results showed that Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy outcomes compared with placebo, and the safety profile was consistent with previous studies.

LANCET (2023)

Article Medicine, General & Internal

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewe, Iain B. McInnes, Philip J. Mease, Christopher T. Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D. Gladman, Laure Gossec, Alice B. Gottlieb, Diamant Thaci, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

Summary: This study compared the efficacy and safety of Bimekizumab with placebo in patients with active psoriatic arthritis. The results showed that Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes compared with placebo. The safety profile of Bimekizumab was consistent with previous studies.

LANCET (2023)

Letter Rheumatology

Response to: Correspondence on ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update by Ramiro et al

Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Desiree van der Heijde

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Multidisciplinary Sciences

Clinical courses, impact and prognostic indicators for a persistent course of low back pain: Results from a population-based cohort study

Luis Antunes Gomes, Ana Maria Rodrigues, Jaime Branco, Helena Canhao, Eduardo Brazete Cruz

Summary: This study aimed to investigate the courses of chronic low back pain (CLBP), its cumulative impact, and the indicators for the persistence of pain. The results showed that patients with CLBP could follow a persistent or relapsing course of pain in the long-term. Being female, presenting depressive symptoms, having a manual job, and higher disability at baseline were predictors of a persistent course of LBP.

PLOS ONE (2023)

Article Rheumatology

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra

Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Correction Rheumatology

Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target (kead155, 2023)

Janne W. Bolt, Caroline J. Aalbers, Laura Walet, Leonieke J. J. van Mens, Christiaan van Denderen, Irene van der Horst-Bruinsma, Lisa G. M. van Baarsen, Robert Landewe, Marleen G. H. van de Sande

RHEUMATOLOGY (2023)

Article Rheumatology

What do patients on methotrexate need and expect at the clinic? An online patient survey

Teresa Oton, Loreto Carmona, Jose Luis Andreu

Summary: This study assessed the experience and needs of patients receiving MTX treatment through an online survey. The results showed that patients were not satisfied with the quality of information provided by clinics and had a demand for more and better-quality written or web-based information.

RHEUMATOLOGY INTERNATIONAL (2023)

暂无数据